Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Emberson

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Gaceta Medica De Mexico|June 18, 2025
Complex relationship between Amerindian ancestry and obesity in the Mexican populationPaulina Baca, Elizabeth Barrera, Pablo A Kuri, et al.
Mayo Clinic Proceedings|November 6, 2017
The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysisSimon D S Fraser, Anthony Fenton, Scott Harris, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2016
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)Natalie Staplin, Richard Haynes, William G Herrington, et al.
The Lancet. Diabetes & Endocrinology|August 2, 2016
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials, William Herrington, Jonathan Emberson, et al.
BMC Cancer|July 17, 2016
Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studiesGermaine Wong, Natalie Staplin, Jonathan Emberson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2017
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal ProtectionMarion M Mafham, Natalie Staplin, Jonathan Emberson, et al.
Journal of the American Society of Nephrology : JASN|May 3, 2014
Effects of lowering LDL cholesterol on progression of kidney diseaseRichard Haynes, David Lewis, Jonathan Emberson, et al.
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
International Journal of Epidemiology|February 24, 2019
Cohort Profile: the Cuba Prospective StudyNurys Armas Rojas, Ben Lacey, Sarah Lewington, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Gaceta Medica De Mexico|June 18, 2025
Complex relationship between Amerindian ancestry and obesity in the Mexican populationPaulina Baca, Elizabeth Barrera, Pablo A Kuri, et al.
Mayo Clinic Proceedings|November 6, 2017
The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysisSimon D S Fraser, Anthony Fenton, Scott Harris, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2016
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)Natalie Staplin, Richard Haynes, William G Herrington, et al.
The Lancet. Diabetes & Endocrinology|August 2, 2016
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials, William Herrington, Jonathan Emberson, et al.
BMC Cancer|July 17, 2016
Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studiesGermaine Wong, Natalie Staplin, Jonathan Emberson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2017
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal ProtectionMarion M Mafham, Natalie Staplin, Jonathan Emberson, et al.
Journal of the American Society of Nephrology : JASN|May 3, 2014
Effects of lowering LDL cholesterol on progression of kidney diseaseRichard Haynes, David Lewis, Jonathan Emberson, et al.
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
International Journal of Epidemiology|February 24, 2019
Cohort Profile: the Cuba Prospective StudyNurys Armas Rojas, Ben Lacey, Sarah Lewington, et al.
Pageof 11